Merck & Co. Inc. Purchases Shares of 772,165 Kymera Therapeutics, Inc. $KYMR

Merck & Co. Inc. acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 772,165 shares of the company’s stock, valued at approximately $88,544,161,000. Kymera Therapeutics makes up approximately 16.8% of Merck & Co. Inc.’s investment portfolio, making the stock its 3rd biggest position.

Several other large investors have also modified their holdings of the stock. Smartleaf Asset Management LLC grew its position in shares of Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after buying an additional 424 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares during the last quarter. Osaic Holdings Inc. increased its position in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Kymera Therapeutics by 27.5% during the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after purchasing an additional 98 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Kymera Therapeutics in the 4th quarter valued at about $63,000.

Kymera Therapeutics Price Performance

NASDAQ KYMR opened at $121.41 on Tuesday. The business has a 50 day moving average price of $106.11 and a 200 day moving average price of $90.76. The company has a market capitalization of $10.10 billion, a P/E ratio of -37.47 and a beta of 1.95. Kymera Therapeutics, Inc. has a 1-year low of $39.84 and a 1-year high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.09. The company had revenue of $65.00 million for the quarter, compared to the consensus estimate of $32.78 million. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.Kymera Therapeutics’s quarterly revenue was up 465.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.95) earnings per share. On average, research analysts expect that Kymera Therapeutics, Inc. will post -3.78 earnings per share for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In related news, CFO Bruce N. Jacobs sold 77,109 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $114.96, for a total value of $8,864,450.64. Following the sale, the chief financial officer directly owned 244,883 shares of the company’s stock, valued at approximately $28,151,749.68. This represents a 23.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bruce Booth sold 467,878 shares of Kymera Therapeutics stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $110.29, for a total transaction of $51,602,264.62. Following the transaction, the director owned 472,267 shares of the company’s stock, valued at approximately $52,086,327.43. The trade was a 49.77% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 3,604,813 shares of company stock worth $387,557,004. Corporate insiders own 15.98% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on KYMR. Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Bank of America upped their price target on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Canaccord Genuity Group increased their price target on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a research note on Friday, June 26th. Citigroup reiterated a “buy” rating on shares of Kymera Therapeutics in a research note on Thursday, August 6th. Finally, Royal Bank Of Canada downgraded shares of Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and raised their price objective for the stock from $106.00 to $115.00 in a research report on Monday, July 13th. Twenty analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $125.65.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.